【摘要】 目的:分析给予急性冠脉综合征患者进行早期阿托伐他汀联合依折麦布临床效果。方法:从2013年3月—2015年11月我院共收治急性冠脉综合征患者98例,随机分为2组,实验组49例,给予患者进行阿托伐他汀联合依折麦布,对照组49例,给予患者进行阿托伐他汀治疗。结果:实验组患者在治疗4周后,和治疗之前相比较,患者体内TC、TG、LDL-C都显著下降,两者具有差异性(P<0.05),实验组患者体内TC、LDL-C水平比对照组显著下降(P<0.05),而ALT与CK水平无显著升高,无差异性(P>0.05);实验组患者再发心绞痛与心肌梗死例数小于对照组,两者具有差异性(P<0.05),而实验组死亡例数以及ATL和CK与对照组相比,两者无差异性(P>0.05)。结论:给予急性冠脉综合征患者进行早期阿托伐他汀联合依折麦布,可提高患者生活质量,应用价值极高,值得在临床上推广使用。更多还原

【Abstract】 Objective: To analyze the acute coronary syndrome patients given early atorvastatin combined with ezetimibe clinical effect. Methods: In our hospital there were 98 patients with acute coronary syndrome, randomly divided into two groups, the experimental group of 49 patients, patients given atorvastatin ezetimibe combined with the control group, 49 cases, patients were given atorvastatin statin therapy. Results: The patients in the treatment after four weeks, compared to the prior and treatment, patient TC, TG, LDL-C were significantly decreased, both having a difference(P<0.05), the body of the patient in the experimental group TC, LDL-C was significantly lower than that in the control group(P<0.05), while ALT and CK levels were not significantly increased, no significant differences(P>0.05). The experimental group of patients with recurrent angina, myocardial infarction, the number of cases is less than the control group, both have differences(P<0.05), while the experimental group, the number of deaths as well as ATL and CK compared with the control group, there was no difference(P>0.05). Conclusions: Patients with acute coronary syndrome given early atorvastatin combined with ezetimibe can reduce LDL-C levels in patients and reduce angina and other adverse reactions.更多还原